

Decision aid for primary care prescribed glucose monitoring in people with Type 2 diabetes

SCOPE

This document supports the decision-making process for peoples with Type 2 diabetes to ensure they meet the NICE criteria. Primary care prescribed real-time CGM (rtCGM) and intermittently scanned (commonly known as Flash) glucose monitoring (isCGM) is Amber Recommended for eligible patients following the use of this decision aid in a primary care specialist setting. It is Black for those who do not meet the criteria.

For the purposes of this document, we should assume the NICE real time recommendations apply to secondary care provided CGM.

NICE

NICE NG28 was updated in June 2022. It states that adults with type 2 diabetes and on multiple daily insulin injections (2 or more injections per day) should be offered isCGM, if any of the following apply:

- They have recurrent or severe hypoglycaemia
- They have impaired hypoglycaemia awareness
- They have a condition or disability (including a learning disability or cognitive impairment) that means they cannot self-monitor their blood glucose by capillary blood glucose monitoring but could use an isCGM device (or have it scanned for them)
- They would otherwise be advised to self-measure at least 8 times a day

CGM should also be offered to people with insulin-treated diabetes who would otherwise need help from a care worker or healthcare professional to monitor their blood glucose.

NICE NG18 was updated in May 2023. It states to offer real-time continuous glucose monitoring (rtCGM) to children and young people with type 2 diabetes if any of the following apply.

- They have a need, condition or disability (including a mental health need, learning disability or cognitive impairment) that means they cannot engage in monitoring their glucose levels by capillary blood glucose monitoring
- They would otherwise be advised to self-monitor at least 8 times a day
- They have recurrent or severe hypoglycaemia

It also states to consider rtCGM for children and young people with type 2 diabetes who are on insulin therapy and to consider isCGM (commonly referred to as 'flash') for children and young people with type 2 diabetes aged 4 years and over who are on insulin therapy if rtCGM is contraindicated for them or they express a clear preference for isCGM.

APG board date: 1 September 2023 | ICB Approval: 21 September 2023 Type 2 Diabetes Flash Review date: March 2024 (or earlier if there is significant new evidence relating to this recommendation)

Version: 2.0

DO NOT OFFER GLUCOSE MONITORING DEVICES TO THE FOLLOWING ADULTS

- Not using daily insulin injections.
- Using insulin but not meeting any of the NICE criteria above.

Additional information

Primary care provided glucose monitoring (eg FreeStyle Libre 2, Dexcom One, or Gluco Rx Aidex) should only be recommended by healthcare professionals who are trained to use these devices and patients need to be reviewed regularly by a practice or service with access to the blood glucose data provided via the manufacturers' data portals. All healthcare professionals recommending and managing CGMS systems should have additional training in order to utilise these systems.

Monitor and review the person's use of CGM as part of reviewing their diabetes care plan.

Please see the formulary for a full list of current devices available.

Advise people with type 2 diabetes who are using CGM that they will still need to take capillary blood glucose measurements (although they should do this less frequently than they did previously with capillary blood glucose measurements alone). Explain that is because they will need to use capillary blood glucose measurements to check the accuracy of their CGM device and for use as a back-up (for example when their blood glucose levels are changing quickly or if the device stops working). Provide them with enough test strips to take capillary blood glucose measurements as needed.

If a person is offered secondary care provided CGM or primary care prescribed glucose monitoring but cannot or does not want to use any of these devices, offer capillary blood glucose monitoring.

References

- 1. NICE NG28 Type 2 diabetes in adults: management. Published 2 December 2015 and last updated 29 June 2022.
- 2. NICE NG18 <u>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</u> Published 1 August 2015 and last updated 11 May 2023.